Funded Startups in Leiden
The 21 most recent Leiden rounds show a sharp size split: ProQR Therapeutics’ $59M round on 2026-06-25 is the only disclosed amount above $50M, and it dwar…
The 21 most recent Leiden rounds show a sharp size split: ProQR Therapeutics’ $59M round on 2026-06-25 is the only disclosed amount above $50M, and it dwarfs the next-largest disclosed rounds (Ncardia’s $60M on 2021-11-16 and ChannelEngine’s $50M on 2022-03-15 are comparable, but among 2022+ listings the $59M lead stands out). Stage/label coverage is also uneven: “Series Unknown” appears on 5 of the 21 rows (e.g., ProQR Therapeutics on 2026-06-25, Samotics on 2025-01-27, Batavia Biosciences on 2024-04-09, In Ovo on 2023-11-02, and LeydenJar Technologies on 2026-01-28), while “undisclosed” amounts appear on 2 rows (Batavia Biosciences 2024-04-09; 4MedBox 2023-05-23).
The city view is concentrated in Leiden, but the sector mix leans biotech-heavy: Biotechnology appears in 8 of 21 entries (e.g., ProQR Therapeutics 2026-06-25; BIMINI Biotech 2025-01-13; IridescentBio 2023-12-05; Anavo Therapeutics 2023-05-02). Temporally, the latest two disclosed entries cluster in 2026 (Triple Bio on 2026-05-20 and ProQR Therapeutics on 2026-06-25), while the oldest disclosed point in the listing is Ncardia’s 2021-11-16 round (Venture - Series Unknown), giving a multi-year span from 2021-11-16 through 2026-06-25.
Most recent rounds
21 shownRelated listings
Frequently asked
What stands out in round size across Leiden in this list?
ProQR Therapeutics’ $59M on 2026-06-25 is the largest disclosed amount in the 21-row window, and it sits far above most other disclosed rounds (e.g., Samotics $21M on 2025-01-27, Vico Therapeutics $12M on 2024-06-24, and Whispp $820K on 2024-01-09).
Do any sectors appear disproportionately in these 21 Leiden entries?
Biotechnology is the clear concentration, appearing in 8 of 21 rows (ProQR Therapeutics on 2026-06-25, LeydenJar Technologies on 2026-01-28, BIMINI Biotech on 2025-01-13, and others such as IridescentBio on 2023-12-05). Health Care is also frequent but split across multiple stages (e.g., Vico Therapeutics $12M on 2024-06-24; VarmX $37M on 2023-05-25; ExCulture $380K on 2023-12-05).
How much of the activity uses “Series Unknown” or “undisclosed” labels?
“Series Unknown” shows up on 5 of 21 rows (including ProQR Therapeutics 2026-06-25 and Samotics 2025-01-27), while “undisclosed” amounts appear on 2 rows (Batavia Biosciences 2024-04-09; 4MedBox 2023-05-23). This makes stage interpretation incomplete for a notable fraction of the list.
Which part of the timeline is most recent in terms of dated rounds?
The most recent entry is ProQR Therapeutics on 2026-06-25 ($59M), with the next most recent in the window being Triple Bio on 2026-05-20 ($2M). The dated span runs from 2021-11-16 (Ncardia) through 2026-06-25 (ProQR Therapeutics).
Are there outliers worth segmenting for follow-up (size, stage, or sector)?
Yes: in addition to ProQR Therapeutics’ $59M on 2026-06-25, there are small-ticket extremes that help define tails in deal sizing, such as AVIGI Therapeutics $380K on 2025-04-04 and both ExCulture and IridescentBio at $380K on 2023-12-05. On the other end, ChannelEngine’s $50M on 2022-03-15 (Series B) and Ncardia’s $60M on 2021-11-16 (Venture - Series Unknown) act as additional high-value anchors compared to typical $2M–$42M entries.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.